RPRX
Royalty Pharma plc
$56.43
-1.53
(-2.64%)
Mkt Cap
24.27B
Volume
2,288,379
52W Range
34.081-58.84
Sector
Healthcare
Beta
0.42
EPS (TTM)
2.46
P/E Ratio
22.90
Revenue (TTM)
2.44B
Rev Growth (5Y)
+2.3%
EPS Growth (5Y)
+12.7%
AlphaVal · Fair Value
What we estimate one share is worth
$76.17
Undervalued
moderate signal
25.9% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
C
Stable Earnings Power
51.4 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B | 1.81B | 1.79B | 1.60B | 1.88B | 1.65B |
| Net Income | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M | 2.35B | 1.38B | 1.21B | 565.91M | 581.43M |
| EPS | 2.33 | 1.92 | 3.41 | 0.10 | 1.49 | 1.28 | 6.63 | 3.89 | 3.42 | 0.93 | 0.96 |
| Free Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| FCF / Share | 5.76 | 6.21 | 6.68 | 4.90 | 4.86 | 5.24 | 4.71 | 4.57 | 4.00 | N/A | N/A |
| Operating CF | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B | 1.42B | N/A | N/A |
| Total Assets | 19.62B | 18.22B | 16.38B | 16.81B | 17.52B | 16.02B | 12.45B | 11.37B | 11.37B | 10.48B | 10.82B |
| Total Debt | 8.95B | 7.61B | 6.14B | 7.12B | 7.10B | 5.82B | 6.24B | 6.52B | 6.80B | 5.90B | 5.99B |
| Cash & Equiv | 618.70M | 929.03M | 477.01M | 1.71B | 1.54B | 1.01B | 246.20M | 1.92B | 1.38B | 1.67B | 1.72B |
| Book Value | 6.48B | 6.95B | 6.53B | 5.63B | 5.78B | 4.82B | 6.11B | 4.49B | 4.46B | 4.45B | 4.68B |
| Return on Equity | 0.12 | 0.12 | 0.17 | 0.01 | 0.11 | 0.20 | 0.38 | 0.31 | 0.27 | 0.13 | 0.12 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 630.58M | 621.99M | 609.29M | 578.66M | 568.25M | 593.64M | 564.69M | 537.27M | 567.98M | 596.07M | 536.31M | 538.20M |
| Net Income | 295.00M | 214.21M | 288.22M | 30.18M | 238.35M | 208.21M | 543.99M | 102.00M | 4.78M | 494.34M | 72.11M | 227.62M |
| EPS | 0.68 | 0.64 | 1.05 | 0.09 | 0.55 | 0.47 | 1.22 | 0.23 | 0.01 | 1.48 | 0.21 | 0.51 |
| Free Cash Flow | 760.54M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M | 607.82M |
| FCF / Share | 1.76 | 1.92 | 1.63 | 0.86 | 1.37 | 1.66 | 1.58 | 1.46 | 1.48 | 1.72 | 1.28 | 1.35 |
| Operating CF | 760.54M | 827.15M | 702.62M | 363.98M | 596.08M | 742.52M | 703.61M | 658.21M | 664.64M | 772.63M | 573.52M | 607.82M |
| Total Assets | 19.82B | 19.62B | 19.35B | 18.32B | 17.61B | 18.22B | 18.04B | 17.66B | 16.13B | 16.38B | 15.86B | 17.12B |
| Total Debt | 8.96B | 8.95B | 8.97B | 8.00B | 7.62B | 7.61B | 7.61B | 7.60B | 6.14B | 6.14B | 6.13B | 7.13B |
| Cash & Equiv | 586.39M | 619.00M | 938.94M | 631.91M | 1.09B | 929.03M | 950.05M | 1.76B | 843.00M | 477.01M | 936.45M | 2.17B |
| Book Value | 6.89B | 6.48B | 6.41B | 6.35B | 6.69B | 6.95B | 6.87B | 6.48B | 6.50B | 6.53B | 6.14B | 6.28B |
| Return on Equity | 0.04 | 0.03 | 0.04 | 0.00 | 0.04 | 0.03 | 0.08 | 0.02 | 0.00 | 0.08 | 0.01 | 0.04 |
RPRX News
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
RPRX or ACAD: Which Is the Better Value Stock Right Now?
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript